Terumo India introduces advanced liver cancer treatments Occlusafe and LifePearl

Terumo India, the Indian subsidiary of the globally recognized Terumo Corporation, has recently announced the launch of two innovative products, Occlusafe and LifePearl, aimed at enhancing the management of liver cancer. This introduction marks a significant advancement in the Indian healthcare sector, especially for the treatment of hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer in India.

The Growing Challenge of Liver Cancer in India

In India, liver cancer, specifically HCC, is a major health concern with over 20,000 new cases reported annually. The management of this disease varies from surgical interventions to minimally invasive techniques, with Transcatheter Arterial Chemo-Embolization (TACE) being a prominent minimally invasive option. TACE involves blocking the blood supply to the tumor, leading to the death of tumor cells.

Terumo India Launches Occlusafe and LifePearl for Liver Cancer Management

Terumo’s Innovative Solutions: Occlusafe and LifePearl

Terumo India has introduced Balloon-TACE (B-TACE), an advanced therapy for liver cancer management, for the first time in India. Occlusafe, a B-TACE device from Terumo, allows for precise and targeted chemotherapy delivery to the tumor, minimizing damage to surrounding healthy tissues. This innovation not only improves response rates but also reduces the need for repeat treatments, potentially preserving liver function.

LifePearl, another significant addition to liver cancer care by Terumo, facilitates the controlled and sustained release of chemotherapeutic drugs directly at the tumor site within the liver. Both Occlusafe and LifePearl have shown to enhance clinical outcomes in liver cancer patients treated with TACE.

Terumo’s Vision for Healthcare in India

Shishir Agarwal, MD of Terumo India, emphasized the company’s mission to contribute to society through healthcare by bringing the latest Japanese medical technologies to India. He highlighted the potential of Occlusafe and LifePearl in improving the quality of liver cancer care in the country.

Terumo India is committed to expanding its interventional oncology portfolio with innovative therapeutic solutions, aiming to provide a more comprehensive toolkit for cancer care management. The company’s dedication to advancing healthcare in India is underpinned by a deep understanding of the healthcare system, research, and cutting-edge technology.

About Terumo Corporation

A global leader in medical technology, Terumo Corporation, headquartered in Tokyo, Japan, brings a century of experience in developing a wide range of medical devices. Their extensive portfolio includes vascular intervention, cardio-surgical solutions, blood transfusion, cell therapy technology, and everyday clinical medical products.